<DOC>
	<DOCNO>NCT02151838</DOCNO>
	<brief_summary>To assess safety efficacy Highly Active Anti-Retroviral Treatment ( HAART ) Prevention Mother-To-Child Transmission HIV ( PMTCT )</brief_summary>
	<brief_title>The Thai Red Cross Society Prevention Mother-To-Child Transmission HIV ( TRCS PMTCT ) Program</brief_title>
	<detailed_description>1 . To describe characteristic HIV-infected pregnant woman request HAART Thai Red Cross Society PMTCT ( TRCS PMTCT ) program 2 . To study adverse pregnancy outcome among HIV-infected pregnant woman receive HAART 3 . To study adverse event infant born woman receive HAART pregnancy 4 . To evaluate risk factor HAART-related toxicity perinatal HIV transmission 5 . To establish pilot model care HIV-infected pregnant woman middle income country</detailed_description>
	<criteria>Volunteers meet follow criterion consider eligible enrollment study : 1 . HIVinfected pregnant woman ( defined hospital ) 2 . Choose start HAART accord protocol want receive antiretroviral treatment provide health care system 3 . Understand study sign inform consent form . Persons read consent form read study staff give inform consent use thumb print . 4 . Availability followup plan study duration Volunteers meeting follow criterion exclude study : 1.Persons history medical psychiatric disorder interview physical examination accord standard practice , judgment treat physician , would interfere serve contraindication adherence study protocol ability give inform consent .</criteria>
	<gender>Female</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>HIV-infected pregnant woman request HAART TRCSPMTCT</keyword>
</DOC>